Guanhao Biotech Co.,Ltd. (SHE:300238)
China
· Delayed Price · Currency is CNY 14.43
+0.21 (1.48%)
Apr 29, 2026, 3:04 PM CST
Guanhao Biotech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Operating Revenue | 372.84 | 363.52 | 388.8 | 361.02 | 462.6 | Upgrade
|
| Other Revenue | 14.91 | 13.97 | 15.38 | 16.27 | 26.38 | Upgrade
|
| Revenue | 387.75 | 377.48 | 404.18 | 377.29 | 488.98 | Upgrade
|
| Revenue Growth (YoY) | 2.72% | -6.60% | 7.13% | -22.84% | 11.91% | Upgrade
|
| Cost of Revenue | 90.57 | 78.83 | 88.26 | 159.6 | 125.38 | Upgrade
|
| Gross Profit | 297.18 | 298.65 | 315.92 | 217.69 | 363.6 | Upgrade
|
| Selling, General & Admin | 218.15 | 214.63 | 221.9 | 210.31 | 242.05 | Upgrade
|
| Research & Development | 40.97 | 36.16 | 44.5 | 50.52 | 46.62 | Upgrade
|
| Other Operating Expenses | 6.08 | 4.04 | 3.15 | 3.03 | 4.07 | Upgrade
|
| Operating Expenses | 266.72 | 263.39 | 276.27 | 272.77 | 295.44 | Upgrade
|
| Operating Income | 30.46 | 35.26 | 39.65 | -55.08 | 68.16 | Upgrade
|
| Interest Expense | -4.04 | -1.03 | -1.78 | -4.11 | -7.36 | Upgrade
|
| Interest & Investment Income | 2.56 | 1.27 | 1.5 | 2.22 | 2.19 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.17 | -0.12 | -3.52 | -2.34 | 0.58 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.06 | 0.24 | -4.11 | 1.11 | -5.8 | Upgrade
|
| EBT Excluding Unusual Items | 29.22 | 35.62 | 31.74 | -58.2 | 57.77 | Upgrade
|
| Impairment of Goodwill | - | - | - | -214.33 | -0.15 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -10.84 | -3.64 | -41.36 | -4.68 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.01 | 0.03 | 0.92 | 0.03 | 0.33 | Upgrade
|
| Asset Writedown | -0.08 | -4.98 | -0.29 | -3.61 | -0.05 | Upgrade
|
| Other Unusual Items | -1.86 | 8.19 | 3.35 | 24.9 | 28.83 | Upgrade
|
| Pretax Income | 27.28 | 28.02 | 32.09 | -292.58 | 82.06 | Upgrade
|
| Income Tax Expense | 12.49 | 11.41 | 11.02 | 35.06 | 31.32 | Upgrade
|
| Earnings From Continuing Operations | 14.79 | 16.61 | 21.07 | -327.64 | 50.74 | Upgrade
|
| Minority Interest in Earnings | 9.56 | 10.81 | 9.93 | 19.81 | 22.95 | Upgrade
|
| Net Income | 24.35 | 27.42 | 31.01 | -307.82 | 73.69 | Upgrade
|
| Net Income to Common | 24.35 | 27.42 | 31.01 | -307.82 | 73.69 | Upgrade
|
| Net Income Growth | -11.20% | -11.58% | - | - | 58.14% | Upgrade
|
| Shares Outstanding (Basic) | 271 | 274 | 258 | 265 | 263 | Upgrade
|
| Shares Outstanding (Diluted) | 271 | 274 | 258 | 265 | 263 | Upgrade
|
| Shares Change (YoY) | -1.33% | 6.11% | -2.63% | 0.83% | 1.66% | Upgrade
|
| EPS (Basic) | 0.09 | 0.10 | 0.12 | -1.16 | 0.28 | Upgrade
|
| EPS (Diluted) | 0.09 | 0.10 | 0.12 | -1.16 | 0.28 | Upgrade
|
| EPS Growth | -10.00% | -16.67% | - | - | 55.56% | Upgrade
|
| Free Cash Flow | 33.3 | -26.65 | 0.23 | 29.81 | 117.68 | Upgrade
|
| Free Cash Flow Per Share | 0.12 | -0.10 | 0.00 | 0.11 | 0.45 | Upgrade
|
| Gross Margin | 76.64% | 79.12% | 78.16% | 57.70% | 74.36% | Upgrade
|
| Operating Margin | 7.85% | 9.34% | 9.81% | -14.60% | 13.94% | Upgrade
|
| Profit Margin | 6.28% | 7.26% | 7.67% | -81.59% | 15.07% | Upgrade
|
| Free Cash Flow Margin | 8.59% | -7.06% | 0.06% | 7.90% | 24.07% | Upgrade
|
| EBITDA | 51 | 55.85 | 61.16 | -31.56 | 94.51 | Upgrade
|
| EBITDA Margin | 13.15% | 14.79% | 15.13% | -8.37% | 19.33% | Upgrade
|
| D&A For EBITDA | 20.54 | 20.59 | 21.51 | 23.52 | 26.35 | Upgrade
|
| EBIT | 30.46 | 35.26 | 39.65 | -55.08 | 68.16 | Upgrade
|
| EBIT Margin | 7.85% | 9.34% | 9.81% | -14.60% | 13.94% | Upgrade
|
| Effective Tax Rate | 45.80% | 40.73% | 34.33% | - | 38.17% | Upgrade
|
| Revenue as Reported | 387.75 | 377.48 | 404.18 | 377.29 | 488.98 | Upgrade
|
| Advertising Expenses | 10.89 | 10.97 | 12.39 | 9.43 | 15.72 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.